Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC cut its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 56.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 338,056 shares of the company's stock after selling 436,307 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.27% of Organogenesis worth $1,082,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in Organogenesis during the 4th quarter worth approximately $38,000. Palumbo Wealth Management LLC bought a new position in shares of Organogenesis in the fourth quarter worth $65,000. Algert Global LLC bought a new position in shares of Organogenesis in the fourth quarter worth $69,000. PDT Partners LLC bought a new position in shares of Organogenesis in the fourth quarter worth $110,000. Finally, Aquatic Capital Management LLC bought a new position in shares of Organogenesis in the fourth quarter worth $111,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Stock Up 5.2%

Shares of ORGO traded up $0.15 on Friday, hitting $3.03. 991,674 shares of the stock traded hands, compared to its average volume of 1,146,445. The company has a market capitalization of $384.37 million, a PE ratio of -50.50 and a beta of 1.63. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The business has a 50 day simple moving average of $3.82 and a 200 day simple moving average of $3.85. Organogenesis Holdings Inc. has a one year low of $2.28 and a one year high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The firm had revenue of $86.69 million for the quarter, compared to analysts' expectations of $90.77 million. As a group, equities analysts forecast that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Morgan Stanley raised their price objective on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th.

Insider Transactions at Organogenesis

In related news, insider Lori Freedman purchased 142,379 shares of the business's stock in a transaction on Thursday, June 5th. The shares were acquired at an average price of $2.91 per share, for a total transaction of $414,322.89. Following the purchase, the insider now owns 837,437 shares of the company's stock, valued at $2,436,941.67. This trade represents a 20.48% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders acquired 252,264 shares of company stock valued at $725,732. Company insiders own 33.00% of the company's stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.